Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
Simon Couillard(Université de Sherbrooke), Ian Pavord(Oxford BioMedica (United Kingdom)), Maisha Jabeen(Government Sadiq College Women University), Sanjay Ramakrishnan(Oxford BioMedica (United Kingdom)), Annette Laugerud, J. Mark Melhorn(University Hospital of Wales), Timothy Hinks(University of Oxford)
Cited by 169
Related Papers
Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma: A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial
|American Journal of Respiratory and Critical Care Medicine|2009|686
Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
|The Lancet Respiratory Medicine|2015|584
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
|The Lancet Respiratory Medicine|2021|434
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
|The Lancet|2021|310
Severe eosinophilic asthma: a roadmap to consensus
|European Respiratory Journal|2017|187